Clinical Trial Update: Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 study evaluating FLAG-Ida chemotherapy plus pivekimab sunirine (IMGN632) for newly diagnosed adverse-risk acute myeloid leukemia and other high-grade my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Myeloproliferative Neoplasm
• Myelodysplastic Syndrome
• Myeloproliferative Neoplasm

Drugs mentioned

• FLAG-Ida regimen (Fludarabine, cytarabine, idarubicin)
• Pivekimab Sunirine (IMGN632)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING